Ng Zhi Yang, Honeyman Calum, Shoaib Taimur
Aesthet Surg J Open Forum. 2023 Oct 12;5:ojad090. doi: 10.1093/asjof/ojad090. eCollection 2023.
The ideal breast implant does not exist and the choice of implant for breast augmentation is largely based on what surgeons think will be best for their patients.
To evaluate the preliminary results of a new, smooth, round, and opaque breast implant (PERLE, GC Aesthetics; Dublin, Ireland) from a single-center UK aesthetic practice.
Retrospective cohort study of all patients undergoing breast implant surgery with PERLE at the authors' center between January 2021 and December 2022. Outcomes data such as rates of capsular contracture, infection, revision surgery, and synchronous mastopexy were analyzed.
Of the 385 patients identified, 374 (97.1%) had PERLE implants placed by 3 surgeons for primary ( = 290) and secondary breast augmentation ( = 21), and augmentation-mastopexy ( = 63). Capsular contracture occurred in no cases, infection in 1 (0.2%), and revision surgery in 21 patients (5%). The incision used was always submammary, unless a synchronous mastopexy was performed; implants were placed in the subglandular/subfascial plane in the majority of cases (85.3%), and the rest were dual plane (14.7%). Eight revisions were performed in patients undergoing breast augmentation (due to implant displacement in 6 patients, and hematoma and infection in 1 patient each). Fourteen revisions were performed in those undergoing augmentation-mastopexy. The average follow-up time was 18 months.
The authors' early, single-center experience with PERLE implants suggests a safety profile and overall complication rate that is comparable with other modern implants. They will continue to monitor the safety and effectiveness of PERLE and discuss the reasons and evolution in the choice of breast implant.
理想的乳房植入物并不存在，隆胸植入物的选择很大程度上取决于外科医生认为对患者最有利的因素。
评估一种新型、光滑、圆形且不透明的乳房植入物（PERLE，GC Aesthetics；爱尔兰都柏林）在英国一家单中心美容机构的初步效果。
对2021年1月至2022年12月期间在作者所在中心接受PERLE乳房植入手术的所有患者进行回顾性队列研究。分析了诸如包膜挛缩、感染、修复手术和同期乳房上提术等结果数据。
在确定的385例患者中，374例（97.1%）由3名外科医生植入PERLE植入物，用于初次隆胸（n = 290）、二次隆胸（n = 21）和隆胸-乳房上提术（n = 63）。未发生包膜挛缩病例，感染1例（0.2%），21例患者（5%）进行了修复手术。除非进行同期乳房上提术，否则切口均采用乳房下皱襞切口；大多数情况下（85.3%）植入物置于腺体下/筋膜下平面，其余为双平面（14.7%）。隆胸患者中有8例进行了修复手术（6例因植入物移位，1例因血肿，1例因感染）。隆胸-乳房上提术患者中有14例进行了修复手术。平均随访时间为18个月。
作者对PERLE植入物的早期单中心经验表明，其安全性和总体并发症发生率与其他现代植入物相当。他们将继续监测PERLE的安全性和有效性，并讨论乳房植入物选择的原因及演变。
